ميمپارا

main_info

  • trade_name:
  • ميمپارا
  • pharmaceutical_form:
  • FILM COATED TABLETS
  • administration_route:
  • PER OS
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic
  • manufactured_by:
  • AMGEN EUROPE B.V., NETHERLANDS

documents

localization

  • country:
  • ميمپارا
    إسرائيل
  • language:
  • العربية

therapeutic_information

  • therapeutic_group:
  • CINACALCET
  • therapeutic_indication:
  • Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.

status

  • source:
  • Ministry of Health - State of Israel
  • authorization_number:
  • 137303150700
  • authorization_date:
  • 01-10-2012
  • last_update:
  • 09-08-2016

doc_PIL: head_title_medicine_info

1813 ABR0475

1813